Our Platform: The Feldan Shuttle technology
Feldan Therapeutics has developed a protein-based technology platform, the Feldan Shuttle, for direct delivery of proteins inside cells.
The platform has been successfully used on numerous cell types and in several organs by local injection. The Feldan Shuttle allowed the delivery of active nucleases, transcription factors, antibodies and peptides, revealing its potential to cell-based treatments (ex vivo) and in vivo therapies.
This platform can overcome delivery obstacles in the context of therapeutic use by providing a safe and highly efficient approach that alleviates manipulation complexity and that is associated with low regulatory burden.
BRIEF OVERVIEW OF THE MECHANISM OF FELDAN SHUTTLE
Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia.
Krishnamurthy S, Wohlford-Lenane C, Kandimalla S, Sartre G, Meyerholz DK, Théberge V, Hallée S, Duperré AM, Del'Guidice T, Lepetit-Stoffaes JP, Barbeau X, Guay D, McCray PB Jr., Nat Commun. 2019 Oct 28;10(1):4906. doi: 10.1038/s41467-019-12922-y. PMID: 31659165
Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells.
Del'Guidice T, Lepetit-Stoffaes JP, Bordeleau LJ, Roberge J, Théberge V, Lauvaux C, Barbeau X, Trottier J, Dave V, Roy DC, Gaillet B, Garnier A, Guay D.
PLoS One. 2018 Apr 4;13(4):e0195558. doi: 10.1371/journal.pone.0195558. eCollection 2018. PMID:29617431